Journal of Medicinal Chemistry p. 999 - 1001 (2002)
Update date:2022-07-30
Topics:
Callahan, James F.
Burgess, Joelle L.
Fornwald, James A.
Gaster, Laramie M.
Harling, John D.
Harrington, Frank P.
Heer, Jag
Kwon, Chet
Lehr, Ruth
Mathur
Olson, Barbara A.
Weinstock, Joseph
Laping, Nicholas J.
Screening of our internal compound collection for inhibitors of the transforming growth factor β1 (TGF-β1) type I receptor (ALK5) identified several hits. Optimization of the dihydropyrroloimidazole hit 2 by introduction of a 2-pyridine and 3,4-methylenedioxyphenyl group gave 7, a selective ALK5 inhibitor. With this information, optimization of the triarylimidazole hit 8 gave the selective inhibitor 14, which inhibits TGF-β1-induced fibronectin mRNA formation while displaying no measurable cytotoxicity in the 48 h XTT assay.
View MoreContact:86-21-58226973
Address:No 351,Guoshoujing Road, Zhangjiang Hi-tech Park, Pudong, Shanghai, China
Contact:+86-29-88710656
Address:South Tai bai Road, High Tech Development Zone, Xi'an China
Qingdao Pana-Life Biochem Co.,Ltd.
Contact:86-532-87683902
Address:No.967 Dalao Road, Licang Zone, Qingdao City,Shandong, China 266021
Contact:86-28-61993785
Address:No.70-13-21, North Section, Erhuan
Hangzhou Ledun Technology Co.,Ltd.
Contact:86-571-18767088918
Address:No.6 street,XiaSha,Hangzhou,China.
Doi:10.1016/S0040-4039(00)92748-5
(1980)Doi:10.1080/00397919508011404
(1995)Doi:10.1207/S15327914NC372_3
(1946)Doi:10.2307/3627366
()Doi:10.1016/S0022-328X(00)80809-8
(1971)Doi:10.1021/ja01598a062
(1956)
